Stefania Bianzina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stefania Bianzina has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Pasquale Esposito
Unit of Nephrology, Dialysis and Transplantation, AOM-IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
7 shared publications - Antonio Dal Canton
University of Pavia
5 shared publications - Teresa Rampino
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
4 shared publications - Marilena Gregorini
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
3 shared publications - Angela Amigoni
Pediatric Intensive Care Unit, Department of Women’s and Children’s Health, University Hospital of Padova, Padova, Italy
2 shared publications - Antonio Braschi
Department of Anesthesiology and Intensive Care, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
2 shared publications
Latest Publications
- 19 August 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (9) , 677
Analgesia, sedation, and mobilization practices in pediatric patients supported with extracorporeal membrane oxygenation across Europe: an ESPNIC survey
Appropriate analgosedation and mobilization are essential elements of care in critically ill children. On extracorporeal membrane oxygenation (ECMO), analgosedation and mobilization are tailored to individual pharmacokinetics and mobilization risks. We aimed to investigate analgosedation and mobilization practices in pediatric ECMO across Europe. We performed a multicenter cross-sectional survey-based study. We surveyed one experienced physician per pediatric ECMO center in Europe (March–July 2025). Additionally, we investigated differences in practices based on ECMO volume (≤ 10 vs > 10 cases/year) and ICU type (exclusively pediatric ICU vs other ICUs). Among 123 ECMO centers, 96 (77%) responded, across 19 countries. Fifty-two percent of centers managed > 10 ECMO/year; 68% had exclusively pediatric ICUs. Nineteen percent of centers had a dedicated ECMO-analgosedation protocol. Most centers applied the same analgesic (81%) and sedative (80%) strategies used for non-ECMO patients, though higher doses were often reached on ECMO (62%). Morphine and fentanyl were the preferred first-line analgesics, with fentanyl more used in exclusively pediatric ICUs (p = 0.013); midazolam was the preferred first-line sedative (61%) followed by dexmedetomidine (24%); dexmedetomidine, propofol, and ketamine were the most used second- and third-line agents. Analgosedation, iatrogenic withdrawal, and delirium monitoring tools were widely used, yet 16% and 26% of centers did not use any iatrogenic withdrawal syndrome or delirium tools, respectively. Eighty-one percent of centers implemented mobilization; higher ECMO-volume centers implemented mobilization (p = 0.022), awake-ECMO strategies (p = 0.041), and proning (p = 0.009) more frequently compared to lower ECMO-volume centers. Conclusions: Management of analgosedation in pediatric ECMO patients mirrors that used for non-ECMO patients, though higher doses are reached on ECMO. Only 19% of the centers have a dedicated ECMO-analgosedation protocol. Midazolam is still widely used over alpha-agonists. Mobilization practices are particularly implemented in higher ECMO-volume centers. Further research and education are needed to define best practices and improve outcomes for this population. What is Known: • Appropriate analgosedation and mobilization are essential elements of care in critically ill children. On ECMO, analgosedation and mobilization are challenging and should be tailored to individual pharmacokinetics and mobilization risks. • Limited data, evidence, and dedicated guidelines exist on this topic. What is New: • Management of analgosedation in pediatric ECMO patients in Europe largely mirrors that used for non-ECMO patients, though higher maximum doses were reached on ECMO. Only 19% of centers have a dedicated analgosedation protocol for ECMO-patients. Morphine and fentanyl are the most used analgesics. Midazolam is still widely used as first-line sedative, despite recent pediatric guidelines advocating for alpha-agonists. Mobilization practices are particularly implemented in centers with higher ECMO-volume, reflecting a broader cultural shift toward minimizing sedation and promoting rehabilitation. • Further research and standardized education are needed to define best practices and ultimately improve outcomes for this high-risk patient population.
- 19 August 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (9) , 677
Analgesia, sedation, and mobilization practices in pediatric patients supported with extracorporeal membrane oxygenation across Europe: an ESPNIC survey
Appropriate analgosedation and mobilization are essential elements of care in critically ill children. On extracorporeal membrane oxygenation (ECMO), analgosedation and mobilization are tailored to individual pharmacokinetics and mobilization risks. We aimed to investigate analgosedation and mobilization practices in pediatric ECMO across Europe. We performed a multicenter cross-sectional survey-based study. We surveyed one experienced physician per pediatric ECMO center in Europe (March–July 2025). Additionally, we investigated differences in practices based on ECMO volume (≤ 10 vs > 10 cases/year) and ICU type (exclusively pediatric ICU vs other ICUs). Among 123 ECMO centers, 96 (77%) responded, across 19 countries. Fifty-two percent of centers managed > 10 ECMO/year; 68% had exclusively pediatric ICUs. Nineteen percent of centers had a dedicated ECMO-analgosedation protocol. Most centers applied the same analgesic (81%) and sedative (80%) strategies used for non-ECMO patients, though higher doses were often reached on ECMO (62%). Morphine and fentanyl were the preferred first-line analgesics, with fentanyl more used in exclusively pediatric ICUs (p = 0.013); midazolam was the preferred first-line sedative (61%) followed by dexmedetomidine (24%); dexmedetomidine, propofol, and ketamine were the most used second- and third-line agents. Analgosedation, iatrogenic withdrawal, and delirium monitoring tools were widely used, yet 16% and 26% of centers did not use any iatrogenic withdrawal syndrome or delirium tools, respectively. Eighty-one percent of centers implemented mobilization; higher ECMO-volume centers implemented mobilization (p = 0.022), awake-ECMO strategies (p = 0.041), and proning (p = 0.009) more frequently compared to lower ECMO-volume centers. Conclusions: Management of analgosedation in pediatric ECMO patients mirrors that used for non-ECMO patients, though higher doses are reached on ECMO. Only 19% of the centers have a dedicated ECMO-analgosedation protocol. Midazolam is still widely used over alpha-agonists. Mobilization practices are particularly implemented in higher ECMO-volume centers. Further research and education are needed to define best practices and improve outcomes for this population. What is Known: • Appropriate analgosedation and mobilization are essential elements of care in critically ill children. On ECMO, analgosedation and mobilization are challenging and should be tailored to individual pharmacokinetics and mobilization risks. • Limited data, evidence, and dedicated guidelines exist on this topic. What is New: • Management of analgosedation in pediatric ECMO patients in Europe largely mirrors that used for non-ECMO patients, though higher maximum doses were reached on ECMO. Only 19% of centers have a dedicated analgosedation protocol for ECMO-patients. Morphine and fentanyl are the most used analgesics. Midazolam is still widely used as first-line sedative, despite recent pediatric guidelines advocating for alpha-agonists. Mobilization practices are particularly implemented in centers with higher ECMO-volume, reflecting a broader cultural shift toward minimizing sedation and promoting rehabilitation. • Further research and standardized education are needed to define best practices and ultimately improve outcomes for this high-risk patient population.
- 25 April 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 71 (11) , 952-959
Ductus Arteriosus Patency for the Hemodynamic Management of Newborns With Pulmonary Hypertension on Veno-Venous Extracorporeal Membrane Oxygenation
In neonates with pulmonary hypertension (PH) supported on veno-venous extracorporeal membrane oxygenation (VV-ECMO), keeping the ductus arteriosus (DA) open ensures a high cardiac output of well-oxygenated blood through the right to left (R-L) ductal shunt. After PH resolution, timely closure of the patent DA (PDA) prevents pulmonary overcirculation, systemic hypoperfusion, and unsuccessful ECMO weaning. We retrospectively evaluated its impact on the echocardiographic and hemodynamic features of 18 newborns undergoing VV-ECMO because of acute hypoxic respiratory failure in PH. At ECMO start, PDA was left or maintained open for all patients with echocardiographic signs of PH. After ECMO initiation, PDA shunt reverted into left to right (L-R). Twenty-four hours before DA closure, the echocardiographic assessment suggested a drop in pulmonary vascular resistances (PVRs). At 24 and 48 hours after DA closure, cardiac ultrasound confirmed continued improvement of PH. Ductus arteriosus closure is associated with a significant drop in arterial lactates ( p = 0.014) and increase in diastolic blood pressure ( p = 0.037). All patients, except for the two who died on ECMO, were successfully weaned from extracorporeal life support. Overall survival was 61.1%. These preliminary data suggest the feasibility and safety of DA patency manipulation in neonates undergoing VV-ECMO for PH, supporting a VV configuration in this patient population.
- 25 April 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 71 (11) , 952-959
Ductus Arteriosus Patency for the Hemodynamic Management of Newborns With Pulmonary Hypertension on Veno-Venous Extracorporeal Membrane Oxygenation
In neonates with pulmonary hypertension (PH) supported on veno-venous extracorporeal membrane oxygenation (VV-ECMO), keeping the ductus arteriosus (DA) open ensures a high cardiac output of well-oxygenated blood through the right to left (R-L) ductal shunt. After PH resolution, timely closure of the patent DA (PDA) prevents pulmonary overcirculation, systemic hypoperfusion, and unsuccessful ECMO weaning. We retrospectively evaluated its impact on the echocardiographic and hemodynamic features of 18 newborns undergoing VV-ECMO because of acute hypoxic respiratory failure in PH. At ECMO start, PDA was left or maintained open for all patients with echocardiographic signs of PH. After ECMO initiation, PDA shunt reverted into left to right (L-R). Twenty-four hours before DA closure, the echocardiographic assessment suggested a drop in pulmonary vascular resistances (PVRs). At 24 and 48 hours after DA closure, cardiac ultrasound confirmed continued improvement of PH. Ductus arteriosus closure is associated with a significant drop in arterial lactates ( p = 0.014) and increase in diastolic blood pressure ( p = 0.037). All patients, except for the two who died on ECMO, were successfully weaned from extracorporeal life support. Overall survival was 61.1%. These preliminary data suggest the feasibility and safety of DA patency manipulation in neonates undergoing VV-ECMO for PH, supporting a VV configuration in this patient population.
- Open Access
- 27 June 2024
- Published by Springer Nature in Intensive Care Medicine – Paediatric and Neonatal
- Vol. 2 (1) , 1-11
Assessment of self-perceived knowledge of key clinical pharmacology concepts and educational needs among European Paediatric Intensive Care Units: an ESPNIC survey
Background: Knowledge of clinical pharmacology concepts is essential to improve patients’ outcomes. Scarce data is available on the utilisation of these concepts in the paediatric intensive care unit (PICU). We aimed to investigate the self-perceived knowledge of clinical pharmacology concepts, educational needs and identify priorities for pharmacological research across European PICUs. Methods: From July to November 2022 an online survey was distributed to evaluate i) the self-reported knowledge, and ii) application of key pharmacology concepts in clinical practice (using a likert scale from 1 = never apply to 10 = always apply); iii) need for additional education on them; and iv) key areas for future pharmacological research. The survey was distributed to European Society of Paediatric and Neonatal Intensive Care (ESPNIC) members and other European national PICUs societies members. Results: Two-hundred-thirty-seven responses from 149 PICUs were collected. 54% of PICUs reported to have a clinical pharmacologist available for consultation during drug prescription and 65% of them regularly contact them during the prescribing process. Among clinical pharmacology concepts the parameter with the highest self-reported knowledge was half-life (99%) and the lowest were pharmacodynamics and volume-of-distribution (92%). The reported median application of these concepts in clinical practice ranged between 5/10 and 7/10. Most of the respondents reported the need for additional education on specific pharmacology concepts. Reported priorities for drug research mostly involved analgesics/sedatives (87%), antimicrobials (86%), and cardiovascular medications (55%). Conclusions: Self-reported knowledge on clinical pharmacology concepts seems good, but self-perceived clinical application may improve and most of the respondents report a need for additional education. These findings call for concerted multidisciplinary efforts to streamline education and guidelines to fill this gap.
- 27 June 2024
- Published by Springer Nature in Intensive Care Medicine – Paediatric and Neonatal
- Vol. 2 (1) , 1-11
Open AccessAssessment of self-perceived knowledge of key clinical pharmacology concepts and educational needs among European Paediatric Intensive Care Units: an ESPNIC survey
Background: Knowledge of clinical pharmacology concepts is essential to improve patients’ outcomes. Scarce data is available on the utilisation of these concepts in the paediatric intensive care unit (PICU). We aimed to investigate the self-perceived knowledge of clinical pharmacology concepts, educational needs and identify priorities for pharmacological research across European PICUs. Methods: From July to November 2022 an online survey was distributed to evaluate i) the self-reported knowledge, and ii) application of key pharmacology concepts in clinical practice (using a likert scale from 1 = never apply to 10 = always apply); iii) need for additional education on them; and iv) key areas for future pharmacological research. The survey was distributed to European Society of Paediatric and Neonatal Intensive Care (ESPNIC) members and other European national PICUs societies members. Results: Two-hundred-thirty-seven responses from 149 PICUs were collected. 54% of PICUs reported to have a clinical pharmacologist available for consultation during drug prescription and 65% of them regularly contact them during the prescribing process. Among clinical pharmacology concepts the parameter with the highest self-reported knowledge was half-life (99%) and the lowest were pharmacodynamics and volume-of-distribution (92%). The reported median application of these concepts in clinical practice ranged between 5/10 and 7/10. Most of the respondents reported the need for additional education on specific pharmacology concepts. Reported priorities for drug research mostly involved analgesics/sedatives (87%), antimicrobials (86%), and cardiovascular medications (55%). Conclusions: Self-reported knowledge on clinical pharmacology concepts seems good, but self-perceived clinical application may improve and most of the respondents report a need for additional education. These findings call for concerted multidisciplinary efforts to streamline education and guidelines to fill this gap.
- Open Access
- 5 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 142
Extracorporeal Carbon Dioxide Removal: From Pathophysiology to Clinical Applications; Focus on Combined Continuous Renal Replacement Therapy
Lung-protective ventilation (LPV) with low tidal volumes can significantly increase the survival of patients with acute respiratory distress syndrome (ARDS) by limiting ventilator-induced lung injuries. However, one of the main concerns regarding the use of LPV is the risk of developing hypercapnia and respiratory acidosis, which may limit the clinical application of this strategy. This is the reason why different extracorporeal CO2 removal (ECCO2R) techniques and devices have been developed. They include low-flow or high-flow systems that may be performed with dedicated platforms or, alternatively, combined with continuous renal replacement therapy (CRRT). ECCO2R has demonstrated effectiveness in controlling PaCO2 levels, thus allowing LPV in patients with ARDS from different causes, including those affected by Coronavirus disease 2019 (COVID-19). Similarly, the suitability and safety of combined ECCO2R and CRRT (ECCO2R–CRRT), which provides CO2 removal and kidney support simultaneously, have been reported in both retrospective and prospective studies. However, due to the complexity of ARDS patients and the limitations of current evidence, the actual impact of ECCO2R on patient outcome still remains to be defined. In this review, we discuss the main principles of ECCO2R and its clinical application in ARDS patients, in particular looking at clinical experiences of combined ECCO2R–CRRT treatments.
- 5 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 142
Open AccessExtracorporeal Carbon Dioxide Removal: From Pathophysiology to Clinical Applications; Focus on Combined Continuous Renal Replacement Therapy
Lung-protective ventilation (LPV) with low tidal volumes can significantly increase the survival of patients with acute respiratory distress syndrome (ARDS) by limiting ventilator-induced lung injuries. However, one of the main concerns regarding the use of LPV is the risk of developing hypercapnia and respiratory acidosis, which may limit the clinical application of this strategy. This is the reason why different extracorporeal CO2 removal (ECCO2R) techniques and devices have been developed. They include low-flow or high-flow systems that may be performed with dedicated platforms or, alternatively, combined with continuous renal replacement therapy (CRRT). ECCO2R has demonstrated effectiveness in controlling PaCO2 levels, thus allowing LPV in patients with ARDS from different causes, including those affected by Coronavirus disease 2019 (COVID-19). Similarly, the suitability and safety of combined ECCO2R and CRRT (ECCO2R–CRRT), which provides CO2 removal and kidney support simultaneously, have been reported in both retrospective and prospective studies. However, due to the complexity of ARDS patients and the limitations of current evidence, the actual impact of ECCO2R on patient outcome still remains to be defined. In this review, we discuss the main principles of ECCO2R and its clinical application in ARDS patients, in particular looking at clinical experiences of combined ECCO2R–CRRT treatments.
- 1 June 2018
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 71 (6) , A12-A14
Rhabdomyolysis-Associated Acute Kidney Injury
- 1 June 2018
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 71 (6) , A12-A14
Rhabdomyolysis-Associated Acute Kidney Injury
- Open Access
- 11 April 2016
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 1-9
In vivo calibration of esophageal pressure in the mechanically ventilated patient makes measurements reliable
Esophageal pressure (Pes) can provide information to guide mechanical ventilation in acute respiratory failure. However, both relative changes and absolute values of Pes can be affected by inappropriate filling of the esophageal balloon and by the elastance of the esophagus wall. We evaluated the feasibility and effectiveness of a calibration procedure consisting in optimization of balloon filling and subtraction of the pressure generated by the esophagus wall (Pew). An esophageal balloon was progressively filled in 36 patients under controlled mechanical ventilation. VBEST was the filling volume associated with the largest tidal increase of Pes. Esophageal wall elastance was quantified and Pew was computed at each filling volume. Different filling strategies were compared by performing a validation occlusion test. Fifty series of measurements were performed. VBEST was 3.5 ± 1.9 ml (range 0.5–6.0). Esophagus elastance was 1.1 ± 0.5 cmH2O/ml (0.3–3.1). Both Pew and the result of the occlusion test differed among filling strategies. At filling volumes of 0.5, VBEST and 4.0 ml respectively, Pew was 0.0 ± 0.1, 2.0 ± 1.9, and 3.0 ± 1.7 cmH2O (p < 0.0001), whereas the occlusion test was satisfactory in 22 %, 98 %, and 88 % of cases (p < 0.0001). Under mechanical ventilation, an increase of balloon filling above the conventionally recommended low volumes warrants complete transmission of Pes swings, but is associated with significant elevation of baseline. A simple calibration procedure allows finding the filling volume associated with the best transmission of tidal Pes change and subtracting the associated baseline artifact, thus making measurement of absolute values of Pes reliable.
- 11 April 2016
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 1-9
Open AccessIn vivo calibration of esophageal pressure in the mechanically ventilated patient makes measurements reliable
Esophageal pressure (Pes) can provide information to guide mechanical ventilation in acute respiratory failure. However, both relative changes and absolute values of Pes can be affected by inappropriate filling of the esophageal balloon and by the elastance of the esophagus wall. We evaluated the feasibility and effectiveness of a calibration procedure consisting in optimization of balloon filling and subtraction of the pressure generated by the esophagus wall (Pew). An esophageal balloon was progressively filled in 36 patients under controlled mechanical ventilation. VBEST was the filling volume associated with the largest tidal increase of Pes. Esophageal wall elastance was quantified and Pew was computed at each filling volume. Different filling strategies were compared by performing a validation occlusion test. Fifty series of measurements were performed. VBEST was 3.5 ± 1.9 ml (range 0.5–6.0). Esophagus elastance was 1.1 ± 0.5 cmH2O/ml (0.3–3.1). Both Pew and the result of the occlusion test differed among filling strategies. At filling volumes of 0.5, VBEST and 4.0 ml respectively, Pew was 0.0 ± 0.1, 2.0 ± 1.9, and 3.0 ± 1.7 cmH2O (p < 0.0001), whereas the occlusion test was satisfactory in 22 %, 98 %, and 88 % of cases (p < 0.0001). Under mechanical ventilation, an increase of balloon filling above the conventionally recommended low volumes warrants complete transmission of Pes swings, but is associated with significant elevation of baseline. A simple calibration procedure allows finding the filling volume associated with the best transmission of tidal Pes change and subtracting the associated baseline artifact, thus making measurement of absolute values of Pes reliable.
- 4 February 2015
- Published by Wiley in Hemodialysis International
- Vol. 19 (4) , E1-5
Renal involvement in mushroom poisoning: The case of Orellanus syndrome
Although mushroom poisoning is a rare cause of acute renal injury, in some cases it may lead to the development of a severe and irreversible renal failure. Orellanus syndrome is the most important example of organic renal damage related to mushroom consumption. It is caused by the ingestion of orellanine, the main toxin of different types of Cortinarius mushrooms (Cortinarius speciosissimus, C. orellanus, C. orellanoides, etc.), and it is characterized by progressive clinical phases with a predominant kidney involvement, finally requiring renal replacement therapy in about 10% of cases. Renal damage is often late and associated with a histological picture of interstitial nephritis. Diagnosis is essentially clinical and no specific therapy has been shown to be effective in preventing and treating renal damage. Here, we describe the case of a patient with mixed wild mushroom poisoning, presenting the typical clinical signs and course of the Orellanus syndrome. This case offers us the opportunity to review the main clinical features of this severe and little‐known intoxication.
- 4 February 2015
- Published by Wiley in Hemodialysis International
- Vol. 19 (4) , E1-5
Renal involvement in mushroom poisoning: The case of Orellanus syndrome
Although mushroom poisoning is a rare cause of acute renal injury, in some cases it may lead to the development of a severe and irreversible renal failure. Orellanus syndrome is the most important example of organic renal damage related to mushroom consumption. It is caused by the ingestion of orellanine, the main toxin of different types of Cortinarius mushrooms (Cortinarius speciosissimus, C. orellanus, C. orellanoides, etc.), and it is characterized by progressive clinical phases with a predominant kidney involvement, finally requiring renal replacement therapy in about 10% of cases. Renal damage is often late and associated with a histological picture of interstitial nephritis. Diagnosis is essentially clinical and no specific therapy has been shown to be effective in preventing and treating renal damage. Here, we describe the case of a patient with mixed wild mushroom poisoning, presenting the typical clinical signs and course of the Orellanus syndrome. This case offers us the opportunity to review the main clinical features of this severe and little‐known intoxication.
- 30 January 2015
- Vol. 81 (8) , 855-64
Esophageal pressure measurements under different conditions of intrathoracic pressure. An in vitro study of second generation balloon catheters.
The aim of this study was to evaluate in vitro the accuracy of second generation esophageal catheters at different surrounding pressures and filling volumes and to suggest appropriate catheter management in clinical practice. Six different esophageal catheters were placed in an experimental chamber at four chamber pressures (0, 10, 20 and 30 cmH2O) and at filling volumes ranging from 0 to 10 mL. The working volume was defined as the volume range between the maximum (Vmax) and minimum (Vmin) volumes achieving acceptable accuracy (defined by a balloon transmural pressure ± 1 cmH2O). Accuracy was evaluated for a standard volume of 0.5 mL and for volumes recommended by manufacturers. Data are shown as median and interquartile range. In the four conditions of chamber pressure Vmin, Vmax and working volume were 1.0 (0.5, 1.5), 5.3 (3.8, 7.1), and 3.5 (2.9, 6.1) mL. Increasing chamber pressure increased Vmin (rho=0.9; P<0.0001), that reached 2.0 mL (1.6-2.0) at 30 cmH2O. Vmax and working volumes differed among catheters, whereas Vmin did not. By injecting 0.5 mL and the minimum recommended volume by manufacturer, balloon transmural pressure was <-1 cmH2O in 71% and 53% of cases, it was negatively related to chamber pressure (rho=-0.97 and -0.71; P<0.0001) and reached values of -10.4 (-12.4, -9.7) and -9.8 (-10.6, -3.4) at 30 cmH2O. Measuring positive esophageal pressures needs higher injected volumes than usually recommended. The range of appropriate filling volumes is catheter-specific. Both absolute values and respiratory changes of esophageal pressure can be underestimated by an underfilled balloon.
- 30 January 2015
- Vol. 81 (8) , 855-64
Esophageal pressure measurements under different conditions of intrathoracic pressure. An in vitro study of second generation balloon catheters.
The aim of this study was to evaluate in vitro the accuracy of second generation esophageal catheters at different surrounding pressures and filling volumes and to suggest appropriate catheter management in clinical practice. Six different esophageal catheters were placed in an experimental chamber at four chamber pressures (0, 10, 20 and 30 cmH2O) and at filling volumes ranging from 0 to 10 mL. The working volume was defined as the volume range between the maximum (Vmax) and minimum (Vmin) volumes achieving acceptable accuracy (defined by a balloon transmural pressure ± 1 cmH2O). Accuracy was evaluated for a standard volume of 0.5 mL and for volumes recommended by manufacturers. Data are shown as median and interquartile range. In the four conditions of chamber pressure Vmin, Vmax and working volume were 1.0 (0.5, 1.5), 5.3 (3.8, 7.1), and 3.5 (2.9, 6.1) mL. Increasing chamber pressure increased Vmin (rho=0.9; P<0.0001), that reached 2.0 mL (1.6-2.0) at 30 cmH2O. Vmax and working volumes differed among catheters, whereas Vmin did not. By injecting 0.5 mL and the minimum recommended volume by manufacturer, balloon transmural pressure was <-1 cmH2O in 71% and 53% of cases, it was negatively related to chamber pressure (rho=-0.97 and -0.71; P<0.0001) and reached values of -10.4 (-12.4, -9.7) and -9.8 (-10.6, -3.4) at 30 cmH2O. Measuring positive esophageal pressures needs higher injected volumes than usually recommended. The range of appropriate filling volumes is catheter-specific. Both absolute values and respiratory changes of esophageal pressure can be underestimated by an underfilled balloon.
- Open Access
- 10 July 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 140-5
Multiple electrolyte disorders in a neurosurgical patient: solving the rebus
Background It is important to ensure an adequate sodium and volume balance in neurosurgical patients in order to avoid the worsening of brain injury. Indeed, hyponatremia and polyuria, that are frequent in this patient population, are potentially harmful, especially if not promptly recognized. Differential diagnosis is often challenging, including disorders, which, in view of similar clinical pictures, present very different pathophysiological bases, such as syndrome of inappropriate antidiuresis, cerebral/renal salt wasting syndrome and diabetes insipidus. Case presentation Here we present the clinical report of a 67-year-old man with a recent episode of acute subarachnoid haemorrhage, admitted to our ward because of severe hyponatremia, hypokalemia and huge polyuria. We performed a complete workup to identify the underlying causes of these alterations and found a complex picture of salt wasting syndrome associated to primary polydipsia. The appropriate diagnosis allowed us to correct the patient hydro-electrolyte balance. Conclusion The comprehension of the pathophysiological mechanisms is essential to adequately recognize and treat hydro-electrolyte disorders, also solving the most complex clinical problems.
- 10 July 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 140-5
Open AccessMultiple electrolyte disorders in a neurosurgical patient: solving the rebus
Background It is important to ensure an adequate sodium and volume balance in neurosurgical patients in order to avoid the worsening of brain injury. Indeed, hyponatremia and polyuria, that are frequent in this patient population, are potentially harmful, especially if not promptly recognized. Differential diagnosis is often challenging, including disorders, which, in view of similar clinical pictures, present very different pathophysiological bases, such as syndrome of inappropriate antidiuresis, cerebral/renal salt wasting syndrome and diabetes insipidus. Case presentation Here we present the clinical report of a 67-year-old man with a recent episode of acute subarachnoid haemorrhage, admitted to our ward because of severe hyponatremia, hypokalemia and huge polyuria. We performed a complete workup to identify the underlying causes of these alterations and found a complex picture of salt wasting syndrome associated to primary polydipsia. The appropriate diagnosis allowed us to correct the patient hydro-electrolyte balance. Conclusion The comprehension of the pathophysiological mechanisms is essential to adequately recognize and treat hydro-electrolyte disorders, also solving the most complex clinical problems.
- 1 July 2012
- Published by Elsevier in Cellular Immunology
- Vol. 278 (1-2) , 10-15
Mechanisms underlying sCD40 production in hemodialysis patients
- 1 July 2012
- Published by Elsevier in Cellular Immunology
- Vol. 278 (1-2) , 10-15
Mechanisms underlying sCD40 production in hemodialysis patients